Jinxin Fertility Group
Corporate brand
UnclaimedJinxin Fertility Group (01951.HK) is a global assisted-reproduction and women's full-lifecycle health service group.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Jinxin Fertility Group (01951.HK) describes itself as a globally leading integrated provider of women's full-lifecycle management and assisted-reproduction services. Its medical network spans the Chinese mainland, Hong Kong, the United States and Southeast Asia, and its services cover assisted reproduction, genetic screening and counseling, prenatal diagnosis and fetal medicine, integrated pregnancy and maternity care, postpartum rehabilitation, child health, general check-ups, dental, ENT, medical aesthetics and anti-aging, and family health management. Its medical institutions include Chengdu Xinnan Women and Children's Hospital, Shenzhen Zhongshan Maternity and Child Health Hospital, Yunnan Jinxin Jiuzhou Hospital, Kunming Jinxin Hewanjia Maternity Hospital, and HRC Fertility in the United States. The group was listed in Hong Kong in 2019 and has been called China's "first IVF stock."
History
Jinxin Fertility Group traces its origins to 2003, when a team of senior and specialized doctors and management personnel founded the "Jinjiang Reproduction Center" (with Sichuan Jinxin Reproductive Medical Management Co., Ltd. as the main entity), headquartered in Chengdu, Sichuan. The group's milestone timeline includes the 1951 establishment of the Chengdu Second District Maternal and Child Health Station, the 1997 establishment of a reproduction center in Shenzhen, the 1998 birth of Shenzhen's first IVF baby at Shenzhen Zhongshan Maternity and Child Health Hospital, the 2001 establishment of a reproduction center in Chengdu, the 2010 establishment of Chengdu Xinnan Gynecology Hospital, the 2013 granting of an assisted-reproduction license to Chengdu Xinnan Gynecology Hospital, and the 2015 establishment of Sichuan Jinxin Women and Children's Hospital. In 2018 the group acquired HRC Fertility, described as the largest reproduction center on the U.S. West Coast. In 2019 it was listed in Hong Kong and was called China's "first IVF stock." In 2021 Sichuan Jinxin Women and Children's Hospital was rated a national Grade 3A hospital, and the group acquired Hong Kong Fertility Health Center (Gan En Medical) and Hong Kong Assisted Reproduction Center. In 2026 Jinxin Fertility officially opened its Southern Headquarters in Shenzhen, launching a dual-headquarters strategy.
Products and positioning
Globally leading integrated provider of women's full-lifecycle management and assisted-reproduction services; China's largest integrated assisted-reproduction service provider by egg-retrieval cycles.
Assisted reproduction (AIH/AID, IVF-ET/ICSI/PGT)
Fertility preservation (egg/embryo freezing)
Genetic screening and counseling (PGT-A/PGT-M/PGT-SR, NIPT/NIPT-plus)
Prenatal diagnosis and fetal medicine
Integrated pregnancy and maternity care
Postpartum rehabilitation and child health
General check-ups, dental, ENT, medical aesthetics and anti-aging
Family health management
Recent events
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/jinxin-fertility-group · Editorial policy · How profiles are compiled